Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 1.736
5-Year Impact Factor – 2.135
Index Copernicus  – 168.52
MEiN – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2017, vol. 26, nr 4, July, p. 577–579

doi: 10.17219/acem/62353

PubMed ID: 28691422

Publication type: original article

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Hepatitis E virus antibodies in HIV-infected patients and blood donors from western Poland: A preliminary report

Maciej Bura1,A,B,C,D,E,F, Alicja Bukowska2,A,B, Aleksandra Bura3,B,E, Michał Michalak4,C, Iwona Mozer-Lisewska1,A,E,F

1 Department of Infectious Diseases, Hepatology and Acquired Immunodeficiences, Poznan University of Medical Sciences, Poland

2 Regional Blood Center, Poznań, Poland

3 Department of Infectious Diseases, Joseph Strus Multidisciplinary City Hospital, Poznań, Poland

4 Department of Computer Science and Statistics, Poznan University of Medical Sciences, Poland

Abstract

Background. Hepatitis E virus (HEV) infection is an emerging problem in industrialized countries, including Europe. Little data exists on HEV seroprevalence in Poland.
Objectives. The aim of this study was to assess the prevalence of anti-HEV IgG antibodies in Polish patients infected with the human immunodeficiency virus (HIV) and blood donors.
Material and Methods. Two hundred and ten individuals (n = 105 of HIV-infected patients and n = 105 of ageand sex-matched blood donors from the same area; 178 men and 32 women), aged 18-50 (median age: 38 years), were tested for the presence of anti-HEV IgG antibodies with the EUROIMMUN Anti-Hepatitis E Virus (HEV) ELISA (IgG) tests (Lübeck, Germany). Additionally, some simple clinical and laboratory data was collected.
Results. The overall anti-HEV IgG prevalence was 2.4% (5/210). One HIV-positive patient (0.95%) and 4 blood donors (3.8%) were seropositive (p = 0.1745). All the HEV-exposed individuals were men with a history of travel abroad and no icteric disease in the past.
Conclusion. Exposure to HEV infection among Polish HIV patients and blood donors seems to be uncommon. Data on this issue is scarce and conflicting for HIV-infected individuals. Further investigations applying different serological tests and concomitant HEV RNA testing are needed to reliably assess the risk and practical impact of HEV infection in Poland.

Key words

HIV, seroprevalence, blood donors, HEV

References (23)

  1. Bendall R, Legrand-Abravanel F, Xia NS, Ijaz S, Izopet J, Dalton HR. Hepatitis E. Lancet. 2012;379:2477–2488.
  2. Lapa D, Capobianchi MR, Garbuglia AR. Epidemiology of hepatitis E virus in European countries. Int J Mol Sci. 2015;16:25711–25743.
  3. Jardi R, Crespo M, Homs M, et al. HIV, HEV and cirrhosis: Evidence of a possible link from eastern Spain. HIV Med. 2012;13:379–383.
  4. Neukam K, Barreiro P, Macías J, et al. Chronic hepatitis E in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin. Clin Infect Dis. 2013;57:465–468.
  5. Bura M, Michalak M, Chojnicki M, Czajka A, Kowala-Piaskowska A, Mozer-Lisewska I. Seroprevalence of anti-HEV IgG in 182 Polish patients. Postepy Hig Med Dosw. 2015;69:320–326.
  6. Bradley-Stewart AJ, Jesudason N, Michie K, Winter AJ, Gunson RN. Hepatitis E in Scotland: Assessment of HEV infection in two high-risk patient groups with elevated liver enzymes. J Clin Virol. 2015;63:36–37.
  7. Daković Rode O, Jemeršić L, Brnić D, et al. Hepatitis E in patients with hepatic disorders and HIV-infected patients in Croatia: Is one diagnostic method enough for hepatitis E diagnosis? Eur J Clin Microbiol Infect Dis. 2014;33:2231–2236.
  8. Mateos-Lindemann ML, Diez-Aguilar M, Galdamez AL, Galán JC, Moreno A, Pérez-Gracia MT. Patients infected with HIV are at high-risk for hepatitis E virus infection in Spain. J Med Virol. 2014;86:71–74.
  9. Rivero-Juarez A, Martinez-Dueńas L, Martinez-Peinado A, et al. High hepatitis E virus seroprevalence with absence of chronic infection in HIV-infected patients. J Infect. 2015;70:624–630.
  10. Pischke S, Ho H, Urbanek F, et al. Hepatitis E in HIV-positive patients in a low-endemic country. J Viral Hepat. 2010;17:598–599.
  11. Balayan MS, Fedorova OE, Mikhailov MI, et al. Antibody to hepatitis E virus in HIV-infected individuals and AIDS patients. J Viral Hepat. 1997;4:279–283.
  12. Cleland A, Smith L, Crossan C, et al. Hepatitis E virus in Scottish blood donors. Vox Sang. 2013;105:283–289.
  13. Mansuy JM, Bendall R, Legrand-Abravanel F, et al. Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis. 2011;17:2309–2312.
  14. Vollmer T, Diekmann J, Johne R, Eberhardt M, Knabbe C, Dreier J. Novel approach for detection of hepatitis E virus infection in German blood donors. J Clin Microbiol. 2012;50:2708–2713.
  15. Juhl D, Baylis SA, Blümel J, Görg S, Hennig H. Seroprevalence and incidence of hepatitis E virus infection in German blood donors. Transfusion. 2014;54:49–56.
  16. Keane F, Gompels M, Bendall R, et al. Hepatitis E virus coinfection in patients with HIV infection. HIV Med. 2012;13:83–88.
  17. Riveiro-Barciela M, Buti M, Homs M, et al. Cirrhosis, liver transplantation and HIV infection are risk factors associated with hepatitis E virus infection. PLoS One. 2014;9:e103028.
  18. Scotto G, Grisorio B, Filippini P, et al. Hepatitis E virus co-infection in HIV-infected patients in Foggia and Naples in southern Italy. Infect Dis. 2015;47:711–717.
  19. Bendall R, Ellis V, Ijaz S, Ali R, Dalton H. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82:799–805.
  20. Wenzel JJ, Preiss J, Schemmerer M, Huber G, Jilg W. Test performance characteristics of Anti-HEV IgG assays strongly influence hepatitis E seroprevalence estimates. J Infect Dis. 2013;207:497–500.
  21. Dreier J, Juhl D. Autochthonous hepatitis E virus infections: A new transfusion-associated risk? Transfus Med Hemother. 2014;41:29–39.
  22. Avellon A, Morago L, Garcia-Galera Del Carmen M, Munoz M, Echevarría JM. Comparative sensitivity of commercial tests for hepatitis E genotype 3 virus antibody detection. J Med Virol. 2015;87:1934–1939.
  23. Politou M, Boti S, Androutsakos T, Valsami S, Pittaras T, Kapsimali V. Seroprevalence of hepatitis E in HIV infected patients in Greece. J Med Virol. 2015;87:1517–1520.
© Wroclaw Medical University